

# BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Doxorubicin and Cyclophosphamide

**Protocol Code:**

*BRAVAC*

**Tumour Group:**

*Breast*

**Contact Physician:**

*Dr. Karen Gelmon*

## ELIGIBILITY:

- Palliative treatment for patients with advanced breast cancer.

## TESTS:

- Baseline: CBC & diff, bilirubin
- Before each treatment: CBC & diff
- If clinically indicated: bilirubin, creatinine

## PREMEDICATIONS:

- Antiemetic protocol for High/Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

## TREATMENT:

Drug	Dose	BCCA Administration Guideline
doxorubicin (ADRIAMYCIN®)	60 mg/m <sup>2</sup>	IV push
cyclophosphamide	600 mg/m <sup>2</sup>	IV in 100 to 250 mL NS or D5W over 20 min to 1 hour

- Repeat every 21 days x 6 cycles.
- If radiation therapy is required, it is given following completion of chemotherapy (BCCA Cancer Management Manual).

## DOSE MODIFICATIONS:

### 1. Hematological:

ANC (x 10 <sup>9</sup> /L)	Platelets (x 10 <sup>9</sup> /L)	Dose (both drugs)
greater than or equal to 1.5	greater than or equal to 90	100%
1.0-1.49	70-89	75%
less than 1.0	less than 70	delay

### 2. Hepatic dysfunction:

Bilirubin (micromol/L)	Dose
25-50	50% doxorubicin-100% cyclophosphamide
51-85	25% doxorubicin-100% cyclophosphamide
greater than 85	delay

3. **Renal dysfunction:** Dose modification may be required for cyclophosphamide (see BCCA Cancer Drug Manual).

**PRECAUTIONS:**

1. **Cardiac Toxicity:** Doxorubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction. Cardiac assessment recommended if lifelong dose of 400 mg/m<sup>2</sup> to be exceeded (see BCCA Cancer Drug Manual).
2. **Extravasation:** Doxorubicin causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.
3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

**Call Dr. Karen Gelmon or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

Date revised: 1 June 2011 (Infusion section revised)